Ticker League

Relmada Therapeutics (RLMD) Free Cash Flow Bridge

Pinpoint what moved Relmada Therapeutics's free cash flow from TTM through Q1 2025 to TTM through Q1 2026 — operating cash flow shifts and capex changes, each driver sized in dollars.

TTM

FCF YoY

+24.65%

OCF YoY

+24.65%

Capex Change

+0.0

FCF Conversion Δ

Free cash flow bridge for Relmada Therapeutics (RLMD) — TTM through Q1 2026 vs TTM through Q1 2025

Δ Free cash flow: $14.00M

FCF bridge breakdown for Relmada Therapeutics (RLMD) — TTM through Q1 2026 vs TTM through Q1 2025

  • Prior Free Cash Flow−$56.79M
  • Operating Cash Flow$14.00M
  • Capital Expenditure$0.00
  • Free Cash Outflow−$42.79M
Identity check: drivers reconcile to ΔNI within $1.00
Want to see how cash flow is built up?Cash Flow Waterfall

Frequently asked questions

Data & methodology

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation